Nature Communications (Feb 2016)
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells
- James Taggart,
- Tzu-Chieh Ho,
- Elianna Amin,
- Haiming Xu,
- Trevor S. Barlowe,
- Alexendar R. Perez,
- Benjamin H. Durham,
- Patrick Tivnan,
- Rachel Okabe,
- Arthur Chow,
- Ly Vu,
- Sun Mi Park,
- Camila Prieto,
- Christopher Famulare,
- Minal Patel,
- Christopher J. Lengner,
- Amit Verma,
- Gail Roboz,
- Monica Guzman,
- Virginia M. Klimek,
- Omar Abdel-Wahab,
- Christina Leslie,
- Stephen D. Nimer,
- Michael G. Kharas
Affiliations
- James Taggart
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Tzu-Chieh Ho
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Elianna Amin
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Haiming Xu
- Memorial Sloan Kettering Cancer Center, Cancer Biology Program
- Trevor S. Barlowe
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Alexendar R. Perez
- Computational Biology Program Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Institute
- Benjamin H. Durham
- Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program
- Patrick Tivnan
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Rachel Okabe
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Arthur Chow
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Ly Vu
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Sun Mi Park
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Camila Prieto
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- Christopher Famulare
- Department of Medicine, Memorial Sloan Kettering Cancer Center, Leukemia Service
- Minal Patel
- Department of Medicine, Memorial Sloan Kettering Cancer Center, Leukemia Service
- Christopher J. Lengner
- Department of Animal Biology, Department of Cell and Developmental Biology and Institute for Regenerative Medicine, Schools of Veterinary Medicine and Medicine, University of Pennsylvania
- Amit Verma
- Montefiore Medical Center, Albert Einstein College of Medicine
- Gail Roboz
- Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College
- Monica Guzman
- Division of Hematology and Medical Oncology, Department of Medicine and Pharmacology, Weill Cornell Medical College, Cornell University
- Virginia M. Klimek
- Department of Medicine, Memorial Sloan Kettering Cancer Center, Leukemia Service
- Omar Abdel-Wahab
- Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program
- Christina Leslie
- Computational Biology Program Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Institute
- Stephen D. Nimer
- Department of Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
- Michael G. Kharas
- Molecular Pharmacology and Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/ncomms10739
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 8
Abstract
Several studies have recently demonstrated the role of the MSI2 RNA binding protein in normal and malignant haematopoietc stem cells. In this study, the authors show that MSI2 is required for maintaining myelodysplastic syndrome stem cells in mice and that MSI2 expression predicts poor prognosis in patients affected by this disease.
